| Prev Close | 22.22 |
| Day Low/High | 21.27 / 22.45 |
| 52 Wk Low/High | 13.67 / 27.80 |
Exelixis, Inc. (EXEL)
21.32
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 310.24B |
| Market Cap | 6.89B |
| P/E Ratio | 46.29 |
| Div & Yield | N.A. (N.A) |
Latest News
Biotech M&A Picks Up: Lessons for Investors and Potential Targets
The euphoria in biotech stocks Monday was a nice change of pace. It also brought to the forefront some lessons about M&A in this industry.
2 Candidates to Consider as Biotech Buyout Activity Picks Up
A handful of deals have been announced this week alone and they give rise to expectations of more acquisitions to come.
It's Options Expiration Day, and I'm Cashing In
Covered call options provide downside protection for holders of the underlying stock and can yield nice profits, too.
Exelixis Charts Are Pointed Higher, Look to Buy a Dip
Aggressive traders could go long EXEL on available weakness.
Keeping Sane, the Profitable Way: How I'm Playing This Market
I continue to shuttle new money into the market on declines using buy-write option strategies.
4 Biotech Stocks I'm Targeting Now
I've stayed primarily to those names that have plenty of cash on the balance sheet and should be just fine once saner heads prevail.
These Biotech Stocks Caught My Attention
Trade continues to be listless and in a relatively tight trading range as markets try to end a solid week for investors. Equities are pretty flat across the board. I would not be surprised to see some profit taking later in the day. Cashing in some ...
Adding to My Biotech Positions When Profit-Taking Hits
Here's my strategy which has worked particularly well.
2 Potential Targets as Biotech Acquisition Activity Heats Up
TG Therapeutics and Exelixis could find themselves on the shopping lists of other companies.
2 Midcaps to Watch Should Pfizer-Array Deal Spark M&A Fever in Biotech Land
These two firms have successful drugs and could make nice additions for larger companies.
A Six-Pack of Biotech Best Bets
Ironically, some experts now see biotech as a safe haven as the sector remains unaffected by trade wars and other global headwinds.
News Surrounds 3 Small Biotechs, With a Merger Claiming One
Two companies in pet pharmaceuticals plan to combine, while two other concerns are worth a look based on developments in their respective spaces.
How I Use Options to Mitigate Risk and Create Income
Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.
Rules of Biotech Investing Change, and So Must Biotech Investors
One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.
Roche Deal for Spark Therapeutics Shows Biotech M&A Spark Hasn't Died
Acquisition deals for biotech companies at the start of 2019 are giving the sector a nice boost; here are other names that could be merger candidates.
These 'Small Ball' Names Will Outperform the Market in 2019
Investors are already more focused on what lies ahead when Q1 results start in early April.
My 2 Top Stock Picks for 2019
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
Celgene Deal Gets the M&A Ball Rolling in the New Year
It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.
3 Profitable Small Biotech Names to Consider
Exelixis Inc., ANI Pharmaceuticals and Supernus Pharmaceuticals should not need to raise more capital in the foreseeable future.
Here's a Handful of Ways to Navigate Biotech's Choppy Seas
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
Here's How I'm Playing Biotech Now
I continue to deploy 'dry powder' into the biotech sector on dips using Buy-Write option strategies.
Small Biotechs Finally Join in Market Rebound
Exelixis Inc. and Aratana Therapeutics in particular surge after posting solid results Thursday.
3 Small Biotech Stocks to Watch in the Fourth Quarter
These are just a few of the names I expect to do well to close out 2018.
3 Small Biotechs on My Q4 Watch List
These are a few of the names I expect to do well to close out 2018.
Synchrony, Exelixis Look Like Good Values
The credit card provider and the biotech concern appear cheap relative to their potential.
Two Oncology Stocks I Like Now
M&A activity should pick up in the biotech space.
Which Hot Biotech Name Will Be Acquired Next?
Your burning biotech questions answered in our latest mailbag.
